Importance of gut hormones in gastrointestinal, metabolic, and malignant diseases

Current Opinion in Endocrinology and Diabetes

Volumn 12, Issue 1, 2005, Pages 80-88

  Adrian, Thomas E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer; Disease; Gastrointestinal hormones; Therapy

Indexed keywords

CHOLECYSTOKININ; GASTRIN; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; MOTILIN; PEPTIDE YY; SECRETIN; SOMATOSTATIN DERIVATIVE;

ANOREXIA; CANCER THERAPY; DIABETES MELLITUS; DIARRHEA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HORMONE ACTION; MALABSORPTION; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; OBESITY; REVIEW; SHORT BOWEL SYNDROME; STOMACH PARESIS;

EID: 14944359006     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000150853.32675.e6     Document Type: Review

References (66)

1. Korbonits M, Goldstone AP, Gueorguiev M, et al. Ghrelin-a hormone with multiple functions. Front Neuroendocrinol 2004; 25:27-68. Excellent, comprehensive, and up-to-date review of all aspects of ghrelin, including its chemistry, biological effects, and pathophysiology.
2. Duxbury MS, Waseem T, Ito H, et al. Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. Biochem Biophys Res Commun 2003; 309:464-468. Documents the expression of ghrelin receptors and the effects of the hormone on proliferation, motility, and invasiveness of pancreatic cancer cells.
3. Cassoni P, Ghe C, Marrocco T, et al. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol 2004; 150:173-184. Describes the effects of ghrelin in prostate cancer cells and the involvement of a novel receptor.
4. Hanada T, Toshinai K, Date Y, et al. Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells. Metabolism 2004; 53: 84-88. Describes the relationship between long-term negative energy balance and ghrelin secretion in a mouse cancer cachexia model.
5. Itoh T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin level in under-weight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004. Documents the effect of anorexia caused by pulmonary disease on ghrelin levels.
6. Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003; 9:774-778. Documents effects of cancer cachexia on ghrelin levels.
7. Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145:669-673.
8. Peracchi M, Conte D, Terrani C, et al. Circulating ghrelin levels in celiac patients. Am J Gastroenterol 2003; 98:2474-2478. Documents the effects of celiac sprue, an inflammatory disease of the small intestine, on ghrelin levels.
9. Masaoka T, Suzuki H, Hosoda H, et al. Enhanced plasma ghrelin levels in rats with streptozotocin-induced diabetes. FEBS Lett 2003; 541:64-68. Reports the influence of streptozotocin-induced diabetes on ghrelin levels in the rat.
10. Breidert M, Zimmermann TF, Schneider R, et al. Ghrelin/leptin-imbalance in patients with primary biliary cirrhosis. Exp Clin Endocrinol Diabetes 2004; 112:123-126. Shows the inverse relationship between leptin and ghrelin in primary biliary cirrhosis.
11. Brzozowski T, Konturek PC, Konturek SJ, et al. Exogenous and endogenous ghrelin in gastroprotection against stress-induced gastric damage. Regul Pept 2004; 120:39-51. Investigates the mechanism of the cytoprotective effects of ghrelin in the stomach.
12. Dembinski A, Warzecha Z, Ceranowicz P, et al. Ghrelin attenuates the development of acute pancreatitis in rat. J Physiol Pharmacol 2003; 54:561-573. Documents the protective effect of ghrelin in a rat pancreatitis model.
13. Nwokolo CU, Freshwater DA, O'Hare P, et al. Plasma ghrelin following cure of Helicobacter pylori. Gut 2003; 52:637-640. Investigates the relationship between H. pylori infection and circulating ghrelin concentrations and the effect of eradicating the infection.
14. Murray CD, Emmanuel AV: Ghrelin and Helicobacter pylori. Gut 2004; 53:315.
15. Macadam RC, Borse V, Dodo I, et al. Helicobacter pylori, ghrelin, and obesity. Gut 2004; 53:315-316.
16. Halem HA, Taylor JE, Dong JZ, et al. Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol 2004; 151(suppl 1):S71-S75. Describes a series of analogues of ghrelin that act as agonists and antagonists on two ghrelin receptors. These or similar compounds are likely to be valuable for treatment of cachexia-associated conditions and obesity, respectively.
17. Haigh CR, Attwood SE, Thompson DG, et al. Gasirin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003; 124:615-625. Describes the role of gastrin in development of esophageal metaplasia. Includes a provocative suggestion of a link between use of proton pump inhibitors for treating esophageal reflux disease and the increasing incidence of esophageal adenocarcinoma in recent years.
18. Moore TC, Jepeal LI, Boylan MO, et al. Gastrin stimulates receptor-mediated proliferation of human esophageal adenocarcinoma cells. Regul Pept 2004; 120:195-203. Describes the growth effects of gastrin on esophageal cancer cells and the mechanism involved.
19. Fitzgerald RC, Abdalla S: Gastrin-induced hyperproliferation in Barrett's esophagus. Gastroenterology 2003; 125:1921.
20. Harris JC, Clarke PA, Awan A, et al. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 2004; 64:1915-1919. Describes a possible link between the antiapoptotic effects of gastrin in esophageal metaplasia and development of esophageal cancer.
21. Abdalla SI, Lao-Sirieix P, Novelli MR, et al. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 2004; 10:4784-4792. Links gastrin with the upregulation of cyclo-oxygenase 2 in the esophageal metaplasia to carcinoma sequence.
22. Tang Z, Zhao M, Ji J, et al. Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia. Oncol Rep 2004; 11:333-339. Explores the relationship between gastrin and c-met in intestinal metaplasia and gastric cancer.
23. Zhou JJ, Chen ML, Zhang QZ, et al. Coexpression of cholecystokinin-B/ gastrin receptor and gastrin gene in human gastric tissues and gastric cancer cell line. World J Gastroenterol 2004; 10:791-794. Investigates the expression of gastrin and its receptor in normal gastric mucosa, gastritis tissue, gastric cancer, and a gastric cancer cell line. Provides evidence that gastrin could play a role in gastric cancer progression.
24. Pradeep A, Sharma C, Sathyanarayana P, et al. Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells. Oncogene 2004; 23:3689-3699. Investigates the role of gastrin in cyclin D1 upregulation in gastric cancer.
25. Triantafillidis JK, Merikas E, Govosdis V, et al. Increased fasting serum levels of growth hormone and gastrin in patients with gastric and large bowel cancer. Hepatogastroenterology 2003; 50(suppl 2):cclvi-cclx. Article confirming that serum gastrin levels are increased in colorectal cancer patients.
26. Niv Y, Delpre G, Sperber AD, et al. Hyperplastic gastric polyposis, hypergastrinaemia and colorectal neoplasia: a description of four cases. Eur J Gastroenterol Hepatol 2003; 15:1361-1366. Description of a potential new syndrome involving gastric polyposis, hypergastrinemia, and clonic neoplasia.
27. Gilliam AD, Watson SA, Henwood M, et al. A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 2004; 30:536-543. Investigation of the responses to a gastrin immunogen in gastric cancer patients.
28. Harris JC, Gilliam AD, McKenzie AJ, et al. The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas. Cancer Res 2004; 64:5624-5631. Investigation into the role of gastrin in pancreatic cancer growth and the potential of therapeutic interruption of this pathway.
29. Dockray GJ: Gastrin, growth, and colon neoplasia. Gut 2000; 47:747-748. Review of the role of gastrin gene products and colonic neoplasia.
30. Ahmed S, Budai B, Heredi-Szabo K, et al. High and low affinity receptors mediate growth effects of gastrin and gastrin-Gly on DLD-1 human colonic carcinoma cells. FEBS Lett 2004; 556:199-203. Characterization of the receptor that mediates the growth effects of gastrin-gly in colon cancer cells.
31. 2 receptors. Regul Pept 2004; 122:32-33. Confirmation that gastrin-gly stimulates growth of colon cancer cells via a novel receptor.
32. Lachal S, Ford J, Shulkes A, et al. PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells. Regul Pept 2004; 120: 243-251. Investigates the relationship between PPARα agonists and progastrin in colon cancer cells. Both factors have previously been implicated in development of this cancer.
33. Baba M, Itoh K, Tatsuta M: Glycine-extended gastrin induces matrix metalloproteinase-1 - and -3-mediated invasion of human colon cancer cells through type I collagen gel and matrigel. Int J Cancer 2004; 111:23-31. Investigates the effect of gastrin on colon cancer cell invasion and its mechanism.
34. Cobb S, Wood T, Ceci J, et al. Intestinal expression of mutant and wild-type progastrin significantly increases colon carcinogenesis in response to azoxymethane in transgenic mice. Cancer 2004; 100:1311-1323. Investigates the relationship between progastrin expression and the development of colonic polyps in a rat carcinogenesis model.
35. Krenning EP, Kwekkeboom DJ, Valkema R, et al. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004; 1014:234-245. Promising clinical trial using high-affinity radiolabeled minigastrin to treat metastatic medullary carcinoma of the thyroid.
36. Tonini M, De Giorgio R, De Ponti F: Progress with novel pharmacological strategies for gastro-oesophageal reflux disease. Drugs 2004; 64:347-361. Clinical study investigating cholecystokinin receptor blockade in esophageal reflux disease.
37. Aly A, Shulkes A, Baldwin GS: Gastrins, cholecystokinins and gastrointestinal cancer. Biochim Biophys Acta 2004; 1704:1-10. Review on the role of gastrin and cholecystokinin gene products in gastrointestinal cancers.
38. Reubi JC, Koefoed P, Hansen TO, et al. Procnolecystokinin as marker of human Ewing sarcomas. Clin Cancer Res 2004; 10:5523-5530. Study of the production of gastrin gene products in Ewing sarcomas and their potential as tumor markers.
39. Conwell DL, Zuccaro G Jr, Vargo JJ, et al. An endoscopic pancreatic function test with cholecystokinin-octapeptide for the diagnosis of chronic pancreatitis. Clin Gastroenterol Hepatol 2003; 1:189-194. Description of the use of a simplified endoscopic pancreatic function test using cholecystokinin.
40. Latorre M, Bartolome-Nebreda JM, Garcia-Lopez MT, et al. Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis. Pharmacology 2004; 72:68-76. Pharmacologic profile of a novel cholecystokinin receptor antagonist and its protective effect in a rat pancreatitis model.
41. Raimondo M, Imoto M, DiMagno EP: Rapid endoscopic secretin stimulation test and discrimination of chronic pancreatitis and pancreatic cancer from disease controls. Clin Gastroenterol Hepatol 2003; 1:397-403. Clinical study of a simplified endoscopic pancreatic function test using secretin.
42. Walkowiak J, Nousia-Arvanitakis S, Lisowska A, et al. Serum lipase after secretin stimulation detects mild pancreatic involvement in cystic fibrosis. J Pediatr Gastroenterol Nutr 2004; 38:430-435. Study of serum lipase responses to secretin in cystic fibrosis.
43. Dumasy V, Delhaye M, Cotton F, et al. Fat malabsorption screening in chronic pancreatitis. Am J Gastroenterol 2004; 99:1350-1354. Study that uses secretin-enhanced magnetic resonance cholangiopancreatography.
44. Russo A, Stevens JE, Giles N, et al. Effect of the motilin agonist KC11458 on gastric emptying in diabetic gastroparesis. Aliment Pharmacol Ther 2004; 20:333-338. Investigation of the use of a motilin agonist in gastroparesis.
45. Curry JI, Lander AD, Stringer MD: A multicenter, randomized, double-blind, placebo-controlled trial of the prokinetic agent erythromycin in the postoperative recovery of infants with gastroschisis. J Pediatr Surg 2004; 39:565-569. Clinical trial of a motilin agonist in postoperative recovery of neonates with gastroschisis.
46. Li JJ, Chao HG, Wang H, et al. Discovery of a potent and novel motilin agonist. J Med Chem 2004; 47:1704-1708. Development of a novel motilin agonist for therapy.
47. Kamerling IM, van Haarst AD, Burggraaf J, et al. Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function. Br J Clin Pharmacol 2004; 57:393-401. Clinical testing of a novel motilin antagonist.
48. Orskov C, Hjorth SA, Jensen AD, et al. Typical Danish Caucasian type 2 diabetic patients do not commonly carry genetic variants in GIP and GLP-1 encoding regions of the proGIP and proglucagon genes. Regul Pept 2004; 119:151-154. Study of genetic variants of GIP and GLP-1 in type 2 diabetes.
49. Theodorakis MJ, Carlson O, Muller DC, et al. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 2004; 27:1692-1698. Relationship between GIP and hyperinsulinemia in patients with impaired glucose tolerance.
50. Rask E, Olsson T, Soderberg S, et al. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 2004; 53:624-631. Relationship between GIP and insulin secretion in patients with impaired glucose tolerance.
51. Gault VA, Flatt PR, O'Harte FP: Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 2003; 308:207-213. Review provides an overview of structurally modified analogues of GIP and their potential use as therapeutics for obesity and diabetes.
52. Gault VA, O'Harte FP, Flatt PR: Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 2003; 37:253-263. Review highlights the potential use of enzyme-resistant analogues of GIP for therapy of diabetes and obesity.
53. Ahren B: Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003; 3:365-372. This review focuses on strategies to use GLP-1 agonists to treat diabetes.
54. Vahl TP, D'Alessio DA: Gut peptides in the treatment of diabetes mellitus. Expert Opin Investig Drugs 2004; 13:177-188. This review focuses on strategies to use GLP-1 agonists to treat diabetes.
55. Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26:2929-2940. This excellent review focuses on proteolysis-resistant GLP-1 agonists to treat diabetes.
56. Holz GG, Chepurny OG: Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 2003; 10:2471-2483. Development of proteolysis-resistant analogues of GLP-1 for diabetes therapy.
57. Jeppesen PB: Clinical significance of GLP-2 in short-bowel syndrome. J Nutr 2003; 133:3721-3724. Excellent review on the nature of the short bowel syndrome and the potentially beneficial effects of using GLP-2 analogues to treat this condition.
58. Martin GR, Wallace LE, Sigalet DL: Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2004; 286:G964-G972. Study highlighting the value of GLP-2 in short bowel syndrome.
59. Arthur GL, Schwartz MZ, Kuenzler KA, et al. Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. J Pediatr Surg 2004; 39:448-452. Study exploring the use of GLP-2 in the treatment of inflammatory bowel disease.
60. Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18:2180-2189. Clinical study on the role of GLP-2 in the postprandial reduction of bone resorption.
61. Henriksen DB, Alexandersen P, Byrjalsen I, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004; 34:140-147. Clinical trial confirming the value of GLP-2 in preventing bone resorption. The findings suggest that GLP-2 may be valuable in the prevention or treatment of osteoporosis.
62. Thulesen J, Hartmann B, Hare KJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004; 53: 1145-1150. Investigation into the effect of a stable GLP-2 analogue on the growth of colonic neoplasms in mice.
63. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418:650-654.
64. 2 on insulin-stimulated glucose disposal in mice.
65. Vona-Davis L, Yu A, Magabo K, et al. Peptide YY attenuates transcription factor activity in tumor necrosis factor-alpha-induced pancreatitis. J Am Coll Surg 2004; 199:87-95. Study on the mechanisms of the protective effect of PYY in acute pancreatitis.
66. Kazanjian KK, Towfigh S, McFadden DW: Peptide YY exhibits a mitogenic effect on pancreatic cells while improving acute pancreatitis in vitro. J Surg Res 2003; 114:95-99. Study confirming the protective effect of PYY in acute pancreatitis.